Aptar Pharma and Propeller Health Partner to Develop Digital Medicine Platform Across Therapeutic Areas
May 30 2018 - 8:00AM
Business Wire
Collaboration also includes strategic
investment by Aptar Pharma; will add connectivity to drug-delivery
routes to improve adherence and treatment outcomes
Aptar Pharma, a leading provider of innovative drug delivery
systems, and Propeller Health, a leading digital therapeutics
company, announced plans to collaborate on the launch of a
comprehensive platform to develop digital medicines for multiple
therapeutic areas and diseases.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20180530005729/en/
The digital medicine platform, spanning inhaled, injectable,
nasal and dermal medicine delivery forms, will combine software and
experiences with connected drug delivery devices to more
effectively treat diseases and improve clinical outcomes for
patients.
Aptar Pharma and Propeller will work together with
pharmaceutical and healthcare partners to accelerate the
development, manufacturing and commercialization of digital
medicines for leading marketed and pipeline brands. Digital
medicines can help to personalize treatments, monitor patients in
real-time, detect day-to-day changes in disease condition and
increase patient adherence. Key objectives are to improve patient
outcomes and help contribute to lower healthcare costs.
The collaboration brings together Aptar Pharma’s decades of
expertise in device development, packaging innovation and quality
manufacturing with Propeller’s platform and leading experience in
digital therapeutics design and implementation.
The two companies initially partnered in 2016 to develop the
world’s first fully-integrated connected metered dose inhaler
(cMDI).
Salim Haffar, President of Aptar Pharma, commented, “Aptar
Pharma has been providing innovative drug delivery systems for
nearly 50 years, helping billions of patients around the world.
Today, we are excited to broaden our offerings as we continue this
journey towards improved patient care and clinical outcomes by
growing our partnership with Propeller Health, the leader in their
field of digital therapeutics.”
“Propeller draws on nearly a decade of experience pioneering
digital respiratory medicines and putting them to work in
healthcare organizations around the world,” said David Van Sickle,
co-founder and CEO of Propeller. “We’re excited to expand our
relationship with Aptar and apply our expertise to new diseases.
Our end-to-end infrastructure enables fast, flexible and secure
development and commercialization of digital medicines.”
Propeller and Aptar Pharma will co-market the platform, with
Propeller managing the digital services and Aptar Pharma managing
the device development, manufacturing and supply chain.
In addition to expanding the partnership, Aptar Pharma has made
a strategic equity investment of $10 million in Propeller Health
during their latest funding round.
About Aptar Pharma
Aptar Pharma is part of AptarGroup, Inc. (NYSE: ATR), a leading
global supplier of a broad range of innovative dispensing and
sealing solutions for the beauty, personal care, home care,
prescription drug, consumer health care, injectables, food and
beverage markets. AptarGroup is headquartered in Crystal Lake,
Illinois, with manufacturing facilities in North America, Europe,
Asia and South America. For more information, visit
aptar.com/pharma.
About Propeller Health
Propeller Health is a leading digital therapeutics company
dedicated to the development and commercialization of measurably
better medicines. Propeller creates products to more effectively
treat disease and improve clinical outcomes for patients across a
range of therapeutic areas through connectivity, analytics, and
companion digital experiences. The Propeller platform is used by
patients, physicians and healthcare organizations in the US, Europe
and Asia. For more information, visit www.propellerhealth.com.
This press release contains forward-looking statements. Words
such as “future” and other similar expressions or future or
conditional verbs such as “will” are intended to identify such
forward-looking statements. Forward-looking statements are made
pursuant to the safe harbor provisions of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and are based on our beliefs as well as assumptions
made by and information currently available to us. Accordingly, our
actual results may differ materially from those expressed or
implied in such forward-looking statements due to known or unknown
risks and uncertainties that exist in our operations and business
environment. Additionally, forward-looking statements include
statements that do not relate solely to historical facts, such as
statements which identify uncertainties or trends, discuss the
possible future effects of current known trends or uncertainties or
which indicate that the future effects of known trends or
uncertainties cannot be predicted, guaranteed or assured. For
additional information on these and other risks and uncertainties,
please see our filings with the Securities and Exchange Commission,
including the discussion under “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations” in our Form 10-Ks and Form 10-Qs. We undertake no
obligation to update any forward-looking statements, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180530005729/en/
Media Contacts:Carolyn
PenotAptar Pharma+33 1 39 17 20 38carolyn.penot@aptar.comorMike
PilarzPropeller Health+1 608 709
8729mike.pilarz@propellerhealth.comorInvestor Relations Contact:Matt
DellaMariaAptarGroup, Inc.+1 815 477
0424matt.dellamaria@aptar.com
AptarGroup (NYSE:ATR)
Historical Stock Chart
From Mar 2024 to Apr 2024
AptarGroup (NYSE:ATR)
Historical Stock Chart
From Apr 2023 to Apr 2024